180 Life Sciences Files 8-K: Other Events & Financials
Ticker: FRMM · Form: 8-K · Filed: Dec 12, 2024 · CIK: 1690080
Sentiment: neutral
Topics: corporate-event, filing, financials
TL;DR
180 Life Sciences filed an 8-K on Dec 10th covering other events and financials. Stay tuned for details.
AI Summary
On December 10, 2024, 180 Life Sciences Corp. filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing was made on December 12, 2024, and pertains to events as of December 10, 2024. The company, previously known as KBL Merger Corp. IV, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.
Why It Matters
This 8-K filing provides an update on the company's corporate events and financial reporting, which is crucial for investors to stay informed about the company's status and regulatory compliance.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant negative news or events that would immediately increase risk.
Key Players & Entities
- 180 Life Sciences Corp. (company) — Registrant
- KBL Merger Corp. IV (company) — Former Company Name
- December 10, 2024 (date) — Date of earliest event reported
- December 12, 2024 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
FAQ
What specific "Other Events" are detailed in this 8-K filing for 180 Life Sciences Corp.?
The provided text indicates that the 8-K filing pertains to 'Other Events' but does not specify the nature of these events.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 10, 2024.
What was the previous name of 180 Life Sciences Corp.?
The previous name of 180 Life Sciences Corp. was KBL Merger Corp. IV.
In which state is 180 Life Sciences Corp. incorporated?
180 Life Sciences Corp. is incorporated in Delaware.
What is the SIC code for 180 Life Sciences Corp.?
The Standard Industrial Classification (SIC) code for 180 Life Sciences Corp. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 882 words · 4 min read · ~3 pages · Grade level 13 · Accepted 2024-12-12 08:00:08
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ATNF The NASDAQ Stock Mar
Filing Documents
- ea0224471-8k_180life.htm (8-K) — 41KB
- ea022447101ex99-1_180life.htm (EX-99.1) — 15KB
- 0001213900-24-108054.txt ( ) — 278KB
- atnf-20241210.xsd (EX-101.SCH) — 4KB
- atnf-20241210_def.xml (EX-101.DEF) — 26KB
- atnf-20241210_lab.xml (EX-101.LAB) — 36KB
- atnf-20241210_pre.xml (EX-101.PRE) — 25KB
- ea0224471-8k_180life_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 12, 2024 180 LIFE SCIENCES CORP. By: /s/ Blair Jordan Name: Blair Jordan Title: Interim Chief Executive Officer 2